Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ac-225-based Therapy
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Collaboration
NorthStar, Curadh Enter Agreement for Actinium-225-Based Radiopharmaceuticals
Details : NorthStar will use its technology and expertise to develop selected Curadh radiopharmaceutical targets for solid tumor cancer diagnosis and treatment.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 03, 2024
Lead Product(s) : Ac-225-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?